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Abstract
Background:  Meta-analysis usually restricts the information pooled, for instance using only
randomised,  double-blind,  placebo-controlled  trials.  This  neglects  other  types  of  high  quality
information. This review explores using different information for the combination of paracetamol
1000 mg and codeine 60 mg in acute postoperative pain.
Results:  Randomised, double-blind, placebo-controlled trials of paracetamol 1000 mg and codeine
60 mg had an NNT of 2.2 (95% confidence interval 1.7 to 2.9) for at least 50% pain relief over four
to  six  hours  in  three  trials  with  197  patients.  Computer  simulation  of  randomised  trials
demonstrated 92% confidence that the simulated NNT was within ±  0.5 of the underlying value of
2.2 with this number of patients. The result was supported a rational dose-response relationship
for different doses of paracetamol and codeine in 17 additional trials with 1,195 patients. Three
controlled trials lacking a placebo and with 117 patients treated with of paracetamol 1000 mg and
codeine 60 mg had 73% (95%CI 56% to 81%) of patients with at least 50% pain relief, compared
with 57% (48% to 66%) in placebo controlled trials. Six trials in acute pain were omitted because
of design issues, like the use of different pain measures or multiple dosing regimens. In each
paracetamol 1000 mg and codeine 60 mg was shown to be better than placebo or comparators for
at least one measure.
Conclusions:  Different designs of high quality trials can be used to support limited information
used in meta-analysis without recourse to low quality trials that might be biased.
Background
The use of evidence-based approaches to therapeutic de-
cision making can frequently raise the problem of how to
make decisions when evidence is in limited supply. Often
systematic reviews limit trial inclusion in an attempt to
generate clinical homogeneity and allow sensible meta-
analysis. The problem, though, is that other, useful, in-
formation is omitted. An example of this is the popular
combination of paracetamol with codeine for treatment
of acute and, more frequently, chronic pain. For the com-
bination of 1000 mg paracetamol plus 60 mg codeine, for
instance, there was information on only 127 patients in
two placebo-controlled acute pain studies [1, 2].
Systematic reviews should seek unbiased evidence,
which may limit the number of studies available for anal-
ysis. One approach to resolving the problem of apparent-
ly insufficient evidence may be to assess evidence of
lower methodological quality. The amount of bias that
could result from this approach would be a concern.
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Schultz et al [3] demonstrated that lack of randomisation
is the major source of bias in trials; studies which are not
randomised can lead to overestimation of treatment ef-
fects by up to 40%. Restricting systematic reviews to in-
clude only randomised studies therefore makes sense for
reviews of effectiveness. A classic example is a review of
transcutaneous nerve stimulation for post-operative
pain relief. Randomised studies overwhelmingly showed
no benefit over placebo, while non-randomised studies
did show benefit [4].
Non-blinded studies over-estimate treatment effects by
about 17% [3]. In a review of acupuncture for back pain
[5], the inclusion of both blinded and non-blinded stud-
ies changed the overall conclusion. The blinded studies
showed 57% of patients improved with acupuncture and
50% with control, a non-significant relative benefit of 1.2
(95% confidence interval 0.9 to 1.5). Five non-blinded
studies showed a difference from control, with 67% im-
proved with acupuncture and 38% with control. Here the
relative benefit was significant at 1.8 (1.3 to 2.4).
Trials of poor reporting quality consistently overestimate
the effect of treatment. Using a validated scoring system
for methodological quality [6], studies of lower quality
are likely to overestimate treatment effects [7, 8]. Other
sources of bias may include small trials [9,10,11], covert
duplication [12], and geography [13]. Vickers and col-
leagues [13] showed that trials of acupuncture conducted
in east Asia were universally positive, while those con-
ducted in Australasia, north America or western Europe
were positive only about half the time. Randomised trials
of therapies other than acupuncture conducted in China,
Taiwan, Japan or Russia/USSR were also overwhelm-
ingly positive.
There is also the issue of the overall validity of a ran-
domised trial. In some areas, like acute pain, valid meth-
ods for the conduct of clinical studies have been set out
for many years, and are well understood [14]. There are
therefore many trials that are randomised and double
blind, and conducted on patients with the same initial se-
verity of pain under similar conditions and assessing
identical or similar outcomes over the same time peri-
ods. Trials with low validity are more likely to have a pos-
itive result than those with higher validity [15], seen in
acupuncture for head and neck pain.
It is obviously sensible to avoid bias where it is likely to
occur. That means avoiding studies with designs or fea-
tures where bias is possible. What other strategies re-
main when faced with apparently inadequate
information from the literature? There are four that
could be applied to the particular combination of para-
cetamol 1000 mg plus codeine 60 mg. These are:
1. The number of patients required for the number need-
ed to treat (NNT) to be within ±  0.5 of the true value var-
ies with the efficacy of an analgesic [11]. We can therefore
calculate how confident we can be in an NNT given the
number of patients in the analysis, or calculate the
number of patients needed to reach a required level of
certainty.
2. We can assess evidence from other dose combinations
of paracetamol and codeine and see whether there is a
dose response relationship in placebo-controlled trials.
3. We can assess results for paracetamol 1000 mg plus
codeine 60 mg against results for active comparators in
high quality active controlled and placebo controlled
studies. This can then be compared with systematic re-
views done in similar clinical settings.
4. We can assess paracetamol 1000 mg plus codeine 60
mg in studies which, though randomised and double
blind, had designs that did not allow their inclusion in a
meta-analysis.
We applied these approaches to paracetamol 1000 mg
plus codeine 60 mg through systematic review of the
published literature.
Methods
Full reports of randomised controlled trials of oral para-
cetamol combined with codeine for acute postoperative
pain were sought. Different search strategies were used
to identify eligible reports in MEDLINE (1966 - March
2000), EMBASE (1980 - March 2000), the Cochrane Li-
brary (Issue 3, 2000) and the Oxford Pain Relief Data-
base (1950 - 1994) [16]. Reference lists of retrieved
reports and reviews [1,2] were searched for additional
trials. Abstracts, review articles and unpublished reports
were not considered.
Criteria for inclusion for postoperative pain were: full
journal publication, randomised controlled trials which
included single dose treatment groups of oral paraceta-
mol combined with codeine, double blind design, base-
line postoperative pain of moderate to severe intensity,
patients over 15 years of age, at least 10 patients per
group, and the pain outcome measures of total pain relief
(TOTPAR) or summed pain intensity difference (SPID)
over 4-6 hours or sufficient data provided to allow their
calculation. Pain measures allowed for the calculation of
TOTPAR or SPID were a standard five point pain relief
scale (none, slight, moderate, good, complete), a stand-
ard four point pain intensity scale (none, mild, moderate,
severe) or a standard visual analogue scale (VAS) for
pain relief or pain intensity. Each report was scored for
quality using a three item, 1-5 score, quality scale [6].BMC Medical Research Methodology (2001) 1:1 http://www.biomedcentral.com/1471-2288/1/1
For each trial, mean TOTPAR, SPID, VASTOTPAR or
VASSPID values for each drug group were converted to
%maxTOTPAR by division into the calculated maximum
value [17]. The proportion of patients in each treatment
group who achieved at least 50%maxTOTPAR was calcu-
lated using valid equations [18,19,20]. The number of
patients with >50%maxTOTPAR was then used to calcu-
late relative benefit and NNT for paracetamol plus co-
deine versus placebo. Relative benefit and relative risk
estimates were calculated with 95% confidence intervals
(CI) using a fixed effects model [21]. NNT with 95% con-
fidence intervals was calculated by the method of Cook
and Sackett [22]. A statistically significant difference
from control was assumed when the 95% confidence in-
terval of the relative benefit did not include 1. Confidence
intervals of proportions were calculated according to
Morris and Gardner [23]. Calculations were performed
using Excel v 5.0 on a Power Macintosh G3. Simulations
and calculations of probability were conducted as de-
scribed in Moore et al, 1998 [11].
Results
There were three placebo controlled [24,25,26] and
three active controlled studies [27,28,29] involving para-
cetamol 1000 mg plus codeine 60 mg (Additional mate-
rial: Table 3). Quality scores were 3 or better for all six.
Information on other dose combinations is in Additional
material: Table 4.
In placebo controlled studies of paracetamol 1000 mg
plus codeine 60 mg 65/114 patients given paracetamol
plus codeine had at least 50% pain relief compared with
9/83 for placebo (Table 1). For a single dose of paraceta-
mol/codeine the proportion of patients with at least 50%
pain relief was 57% (48% to 66%). The NNT for at least
50% pain relief over four to six hours was 2.2 (1.7 to 2.9).
Additional analyses undertaken to assess the reliability
of this assessment of paracetamol 1000 mg plus codeine
60 mg included:
1 Assessment of Accuracy
How accurate is the NNT with currently observed group
sizes and event rates? Using the values of the placebo
event rate of 0.11 (9/83) and the paracetamol/codeine
event rate of 0.57 (65/114), we simulated 10,000 trials
with experimental group size of 114 and a control group
size of 83 and counted the proportion in which the simu-
lated NNT was within ±  0.5 of the true NNT of 1.9 [11].
The results showed that 91.9% of simulated trials had an
NNT of 1.8 to 2.6. The probability that the simulated
NNT was within ±  0.5 of the underlying value of 2.2 was
0.92.
How much data would we require to be 95% sure that the
observed NNT is within ±  0.5 of its true value? We an-
swered this question in two ways, both of which consider
the case of equal group sizes. Again the placebo rate of
0.11 and the paracetamol/codeine rate of 0.57 were used.
The first method used the exact probability distribution
[11]. Using a group size of 130 we obtained a probability
of 0.94, and with 140 we obtained 0.95. So the answer
based on the exact distribution is between 130 and 140
per group. The second method used simulation. Using a
group size of 130 the probability was 0.94, and with 140
it was 0.95. So the answer based on the simulation was
again between 130 and 140 per group, a total of 260 to
280 patients.
2 Other dose Combinations of Paracetamol and Codeine
Information was available on 17 comparable studies
[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46]
in which different dose combinations of paracetamol and
Table 1: Summary results for efficacy of paracetamol/codeine combinations from randomised, double-blind, placebo-controlled trials 
in acute pain
At least 50% pain relief At least 50% pain
with paracetamol and relief with placebo
codeine
Paracetamol + Number of Number Percent Number Percent Relative benefit NNT (95% CI)
codeine dose trials /total (95%CI) /total (95%CI) (95% CI)
1000 mg + 60 mg 3 65/114 57 (48-66) 9/83 11(4-18) 4.8 (2.6 to 8.8) 2.2 (1.7 to 2.9)
600/650 mg + 60 mg 13 191/398 48 (43-53) 78/418 19 (15-22) 2.5 (2.0 to 3.1) 3.4 (2.8 to 4.3)
300 mg + 30 mg 4 56/215 26 (20-32) 14/164 9 (4-13) 3.2 (1.8 to 5.6) 5.6 (4.0 to 9.8)
For inclusion there had to be at least two studies.BMC Medical Research Methodology (2001) 1:1 http://www.biomedcentral.com/1471-2288/1/1
codeine were available for at least two trials (Additional
material: Table 4). Quality scores were 3 or better for all.
There were 13 trials comparing paracetamol 600/650
mg plus codeine 60 mg with placebo in acute pain. For
paracetamol plus codeine 191/398 patients had at least
50% pain relief and 78/418 for placebo. For a single dose
of paracetamol/codeine the proportion of patients with
at least 50% pain relief was 48% (43% to 53%). The NNT
for at least 50% pain relief over four to six hours was 3.4
(2.8 to 4.2).
There were four trials comparing paracetamol 300 mg
plus codeine 30 mg with placebo (Table 1). For paraceta-
mol plus codeine 56/215 patients had at least 50% pain
relief and 14/164 for placebo. For a single dose of para-
cetamol/codeine the proportion of patients with at least
50% pain relief was 26% (20% to 32%). The NNT for at
least 50% pain relief over four to six hours was 5.6 (4.0
to 9.8).
Reducing the dose of paracetamol, and reducing the dose
of paracetamol and codeine produced systematic reduc-
tions in the proportion of patients with adequate pain re-
lief, and a concomitant increase in the NNT (Table 1;
Figure 1). Based on information from 20 trials and 727
patients given paracetamol plus codeine and 665 pa-
tients given placebo, there appears to be a rational dose-
response relationship for paracetamol/codeine combi-
nations in acute pain.
3 Active Controlled Trials
We identified three reports of randomised, double blind
trials comparing paracetamol 1000 mg plus codeine 60
mg with active control groups but without a placebo con-
trol ([27,28,29] (Additional material: Table 3). In active
controlled trials the proportion of patients with at least
50% pain relief over four to six hours was 85/117 pa-
tients, or 73% (65% to 81%), compared with 65/114 pa-
tients, or 57% (48% to 66%) in placebo controlled trials.
Combining data from active and placebo controlled tri-
als, 150 of 229 patients, or 66% (59% to 72%), had at
least 50% pain relief with paracetamol 1000 mg plus co-
deine 60 mg (Table 2; Figure 2).
Figure 1
Relative efficacy: Numbers needed to treat for paracetamol/codeine combinations for at least 50 % pain relief over four to six
hours for patients with moderate or severe post-operative pain. The number of patients in the comparison was the number
given paracetamol 1000 mg plus codeine 60 mg together with the number given placebo in the data pooled from trials for each
combination of paracetamol and codeine where there were at least two trials.BMC Medical Research Methodology (2001) 1:1 http://www.biomedcentral.com/1471-2288/1/1
Information on other paracetamol/codeine combina-
tions and other active comparators from active and pla-
cebo controlled studies involving paracetamol and
codeine combinations is shown in Table 2 and Figure 2.
Again there was a rational dose response for paraceta-
mol/codeine combinations, and paracetamol 1000 mg
plus codeine 60 mg compared favourably with effective
doses of non-steroidal anti-inflammatory drugs
(NSAIDs) [14].
4 Trials Omitted from the Meta-Analysis
There were six trials in acute pain, which, though ran-
domised and double blind, had design features that did
not allow their inclusion in the meta-analysis
([47,48,49,50,51,52] Additional material: Table 5). The
trials could not be included because they used different
pain measures, over relatively short periods, or had mul-
tiple dosing regimens that obscured the efficacy of the
first dose. Three had a placebo control. Quality scores
were 3 or better for all six (Additional material: Table 5).
The studies enrolled 907 patients, and there was infor-
mation on 260 patients who took paracetamol 1000 mg
plus codeine 60 mg with initial pain intensity of at least
moderate intensity.
The outcomes of these six trials were not the same as
those used for the meta-analysis. Despite this, the com-
bination of paracetamol 1000 mg plus codeine 60 mg
could be ascertained. In each of the studies paracetamol
1000 mg plus codeine 60 mg was shown to be better than
placebo or comparators for at least one measure (Addi-
tional material: Table 5). Where effects of paracetamol
1000 mg plus codeine 60 mg on pain intensity was
graphically displayed [49, 51, 52], large reductions in
pain intensity were obtained within about one hour.
Discussion
It can be the case that attempts to practice evidence
based medicine come up against the problem that there
is no evidence, or relatively little evidence. Reviews of pa-
racetamol and codeine [1, 2] revealed that the combina-
tion of paracetamol 1000 mg plus codeine 60 mg was
apparently highly effective, with an NNT of 1.9, but this
was derived from only 127 patients in two trials. Using
evidence from sources other than direct comparisons of
paracetamol/codeine with placebo buttresses the con-
clusion of these earlier reviews.
Firstly we uncovered information about another trials
that increased the number of patients to 197. The inclu-
sion of the third trial barely changed the NNT from 1.9 to
2.2. Unpublished information from a fourth study is
presently being sought.
We know that the amount of information required to be
sure that an NNT is within ±  0.5 of the true value varies
depending on the efficacy of treatment [11, 53]. Where
efficacy is high, the requirement is for small numbers of
patients. Where efficacy is low, the requirement is for
large numbers of patients. For paracetamol 1000 mg
plus codeine 60 mg, calculations show that with 197 pa-
tients we can be about 92% confident that the NNT ob-
Table 2: Summary results for efficacy of paracetamol/codeine combinations and active comparators in randomised, double-blind, ac-
tive- and placebo-controlled trials in acute pain
Drug/dose Number of Patients with at Percentage
trials least 50% pain (95%CI)
relief/total
Paracetamol 300 mg + codeine 30 mg 3 67/272 25 (20 to 30)
Codeine 60 mg 3 24/72 33 (22 to 44)
Ibuprofen 400 mg 2 28/72 39 (28 to 50)
Paracetanol 600/650 mg 10 135/311 43 (38 to 49)
Paracetamol 1000 mg 4 64/151 42 (35 to 50)
Paracetamol 600 mg + codeine 60 mg 13 191/398 48 (43 to 53)
Diflusinal 500 mg 3 54/90 60 (50 to 70)
Ketorolac 10 mg 3 75/117 64 (55 to 73)
Diflusinal 1000 mg 3 61/92 66 (57 to 76)
Paracetamol 1000 mg + codeine 60 mg 6 150/229 66 (59 to 72)
Flurbiprofen 50 mg 3 69/99 70 (61 to 79)
Flurbiprofen 100 mg 3 70/92 76 (67 to 85)BMC Medical Research Methodology (2001) 1:1 http://www.biomedcentral.com/1471-2288/1/1
tained is within ±  0.5 of the true value, close to the
conventionally accepted value of 95%. To be within the
95% limits we would need information from a further 60
to 80 patients.
Biological plausibility derives also from a substantial
dose response relationship with the placebo controlled
studies as the doses of paracetamol and of paracetamol
and codeine increase. Seventeen additional studies of
high quality (randomised, double blind, with clear entry
criteria and outcomes measures) with 1195 additional
patients demonstrated this (Table 1; Figure 1). Dose re-
sponse was also shown when information from placebo
and active controlled trials was pooled to examine the
overall percentage of patients with at least 50% pain re-
lief (Table 1).
This type of analysis additionally demonstrated that in
trials examining paracetamol/codeine combinations, the
paracetamol 1000 mg plus codeine 60 mg combination
was much better than either paracetamol 1000 mg or co-
deine 60 mg alone (Table 2; Figure 2). There was clear
separation between the lower confidence interval for pa-
racetamol 1000 mg plus codeine 60 mg (59%) and the
higher confidence interval for paracetamol 1000 mg
(50%) and codeine 60 mg (44%). This confirms the add-
ed benefit seen with this combining codeine with para-
cetamol in a previous review [1].
Moreover, paracetamol 1000 mg plus codeine 60 mg
demonstrated efficacy similar to effective doses of
NSAIDs drugs tested in the selfsame trials (Table 2; Fig-
ure 2). There is now considerable and growing evidence
on the effectiveness of NSAIDs as analgesics in acute
pain [54, 55]. While ibuprofen 400 mg performed rela-
tively poorly in two trials here, pooled information from
large numbers of studies show it to be an effective anal-
gesic with an NNT of 2.7 (2.5 to 3.0) [54]. Ketorolac has
also been shown to be effective orally; the 10 mg dose had
an NNT of 2.6 (2.3 to 3.1) [55]. In trials involving
NSAIDs these effective analgesics are no better than pa-
racetamol/codeine combinations.
Only six randomised comparisons of paracetamol 1000
mg plus codeine 60 mg with placebo or other analgesics
without placebo were available for analysis using meth-
ods that have become traditional for analysis in acute
pain [14]. This number was doubled by examining stud-
ies that were randomised and double blind, but which
used different pain intensity or relief outcomes, or other
study designs. These additional six studies confirmed
that paracetamol 1000 mg plus codeine 60 mg was an ef-
fective analgesic in acute pain.
Taken together, this approach shows two things. There is
considerable supportive evidence for the conclusion that
paracetamol 1000 mg plus codeine 60 mg is an effective
Figure 2
Efficacy of paracetamol/codeine combinations and active comparators in randomised, double-blind, active- and placebo-con-
trolled trials in acute pain.BMC Medical Research Methodology (2001) 1:1 http://www.biomedcentral.com/1471-2288/1/1
analgesic with a low NNT. This support could be pro-
duced without resource to low quality studies, or those
with known propensity for bias.
It will not always be possible to extend knowledge
though high quality and essentially bias free trials in all
circumstances: acute pain is particularly rich in trials,
and especially those of high quality. Strategies like this
will always be preferable. When placebo controlled trials
are not available conclusions may have to be drawn from
other trials. The techniques described here may be useful
in circumstances where large numbers of high quality
placebo controlled randomised trials are not available to
us. Observational studies of good quality need not give
results that are different from those of randomised trials,
as testified by three recent studies [56,57,58]. But the po-
tential for bias through lack of quality needs always to be
addressed.
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Glossary
SPID Categorical scales use words to describe the magnitude of the pain. 
For analysis numbers are given to the verbal categories (for pain intensity, 
none=0, mild=1, moderate=2 and severe=3). Pain is assessed before the in-
tervention is made and then on multiple occasions. The area under the 
time-analgesic effect curve for pain intensity, or the sum of pain intensity 
differences, is SPID. It is usually, but not always, measured over four to six 
hours.
TOTPAR Categorical scales also use words to describe the magnitude of 
pain relief. The commonest scale to measure pain relief is the five category 
scale (none=0, slight=1, moderate=2, good or lots=3 and complete=4). The 
initial pain relief is taken to be zero, and the pain relief is measured at in-
tervals thereafter. Ideally the area under the time-analgesic effect curve for 
pain relief, or total pain relief, is TOTPAR.
VASSPID Visual analogue scales (VAS), 100 mm lines with left end labelled 
"least possible pain" and right end labelled "worst possible pain" can be used 
to measure pain intensity. Patients mark the line at the point which corre-
sponds to their pain. The scores are obtained by measuring the distance be-
tween the least pain end and the patient's mark, usually in millimetres. The 
area under the time-analgesic effect curve for pain intensity, or the sum of 
pain intensity differences, is VASSPID.
VASTOTPAR Visual analogue scales (VAS), 100 mm lines with left end la-
belled "no relief of pain" and right end labelled "complete relief of pain", can 
be used to measure pain relief. The initial pain relief is taken to be zero, and 
thereafter patients mark the line at the point which corresponds to their 
pain relief. The scores are obtained by measuring the distance between the 
no relief end and the patient's mark, usually in millimetres. The area under 
the time-analgesic effect curve for pain relief, or the sum of total pain relief, 
is VASTOTPAR.
maxTOTPAR The maximum pain relief a patient can obtain is complete re-
lief at the first measurement point, maintained for the whole period of ob-
servation. Thus using the categorical scale, the maximum relief would be 4, 
maintained for six hours, giving a maximum value of TOTPAR of 24. If a pa-
tient scored their pain relief in such a way as to give a TOTPAR of 15, this 
would be 15/24, or 63% of maxTOTPAR.
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